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Background/Introduction: Psychological distress occurs frequently in patients with cancer. Psychological distress
includes mild and severe forms of both anxious and depressive mood states. Literature indicates that effective
management of psychological distress seems to require targeted selection of patients (T), followed by enhanced
care (E), and the application of evidence based interventions. Besides, it is hypothesized that delivering care
according to the stepped care (S) approach results in an affordable program. The aim of the current study is to
evaluate the (cost)-effectiveness of the TES program compared to usual care in reducing psychological distress in
patients with metastatic colorectal cancer (mCRC).
Methods: This study is designed as a cluster randomized trial with 2 treatment arms: TES program for screening
and treatment of psychological distress versus usual care. Sixteen hospitals participate in this study, recruiting
patients with mCRC. Outcomes are evaluated at the beginning of chemotherapy and after 3, 10, 24, and 48 weeks.
Primary outcome is the difference in treatment effect over time in psychological distress, assessed with the Hospital
Anxiety and Depression Scale. Secondary outcomes include quality of life, patient evaluation of care, recognition
and management of psychological distress, and societal costs.
Discussion: We created optimal conditions for an effective screening and treatment program for psychological distress
in patients with mCRC. This involves targeted selection of patients, followed by enhanced and stepped care. Our
approach will be thoroughly evaluated in this study. We expect that our results will contribute to the continuing
debate on the (cost-) effectiveness of screening for and treatment of psychological distress in patients with cancer.
Trial Registration: This trial is registered in the Netherlands Trial Register NTR4034
Keywords: Colorectal cancer, Metastatic disease, Psychological distress, Screening, Quality of life, Cost-effectivenessBackground
Colorectal cancer (CRC) is one of the most prevalent
cancers and causes of cancer-related mortality in devel-
oped countries [1], with over 1.3 million new cancer
cases and 694,000 deaths estimated to have occurred in
2012 worldwide in 2012 [2]. The mean 5-year survival* Correspondence: j.dekker@vumc.nl
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unless otherwise stated.rate is currently 59%. Approximately 40-50% of patients
develop metastatic disease. Life expectancy of patients
with metastatic disease is about 30 months [3].
In patients with cancer there is significant evidence of
psychological distress. Psychological distress is defined
as a multifactorial, unpleasant, emotional experience of a
psychological (cognitive, behavioral, emotional), social
and/or spiritual nature that may interfere with the ability
to cope effectively with cancer, its physical symptoms,
and its treatment. Distress extends along a continuum,
ranging from common normal feelings of vulnerability,
sadness, and fears, to problems that can becomeentral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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tion, and existential and spiritual crisis [4]. Prior studies
indicated that the majority of patients have the ability to
cope with the psychological burden that can be caused
by hearing the diagnosis, suffering from the disease or
its treatment [5,6]. However, although precise estimates
vary with different types and sites of cancer, approximately
30-40% of patients receiving cancer care experience psy-
chological symptoms of distress, such as depression and
anxiety [5,6]. These findings also apply to patients with
CRC: a large proportion of patients seems to suffer from
psychological morbidity [5,7]; the presence of metastases is
associated with even more psychological symptoms [8,9].
Symptoms of psychological distress in patients with
cancer are associated with decreased health-related qual-
ity of life and can have a large impact on the patient’s
functioning [10-12]. Other studies have shown that pa-
tients with psychological distress are usually less satisfied
with the care they received, show non-compliance with
treatment more often [13] and use emergency room ser-
vices more frequently in comparison with patients with-
out psychological distress.
Both psychotherapeutic and pharmacotherapeutic in-
terventions have proven to be effective in treating symp-
toms of psychological distress in patients with cancer
[14-16]. However, a considerable number of patients are
not provided with adequate psychological care, since
psychological needs are often under-recognized in clin-
ical oncology practice [10,17,18]. In order to remediate
this situation, oncology guidelines have recommended to
routinely screen for and treat psychological distress,
thereby integrating psychological care into standard on-
cology practice. Nonetheless, there is lack of evidence
regarding the true benefit of implementation of systemic
screening and treatment of psychological distress in pa-
tients with cancer. A review of seven studies in cancer
care concluded that implementation of distress screen-
ing showed limited evidence of resulting in better pa-
tient outcomes, but that treatment of identified distress
itself is effective in patients with cancer [19]. Results
from two recently published trials stated that the use of
a psychosocial screening instrument among patients
with cancer receiving radiotherapy [20] or chemotherapy
[21] in itself does not sufficiently improve patients’
health-related outcome. In addition, another recent re-
view [17] focusing on studies regarding effectiveness of
screening combined with psychological treatment ob-
tained contradictory results, but confirmed that treat-
ment of psychological distress itself is effective in
patients with cancer.
Studies conducted in both oncology and primary
health care settings [21-25] indicate that merely admin-
istering screening questionnaires in clinical practice does
not improve recognition, but that targeted selection ofpatients may result in improved recognition of psycho-
logical distress by clinicians. Targeted selection of pa-
tients involves administering and scoring of the
screening instrument by someone other than the clin-
ician, with only those with high scores offered a referral
for treatment [22]. These experiences in targeted selec-
tion (or triage) seem promising in improving manage-
ment of psychological distress.
Further, it has been suggested that enhanced care is
needed: screening needs to be followed-up with add-
itional assessments, follow up contacts and monitoring
of the treatment process by adequately trained staff. Also
extra efforts have to be made to enroll patients into ap-
propriate referral services, where evidence-based treat-
ments are provided (19, 20, 23–25). In addition, it has
been stated that depression screening is only effective if
subsequent, adequate treatment is offered. This is the
conclusion from both a systematic review [23] on
screening for depression in primary care, a narrative re-
view [26] on screening for depression in various clinical
settings, and a recent review on screening for psychological
distress in oncology settings [27]. These findings from re-
search conducted in patients with psychological distress
combined with experiences in the area of depression lead
us to hypothesize that targeted screening, enhanced care
and evidence based treatment are essential ingredients of
an effective approach towards screening and treatment of
psychological distress in patients with cancer.
Additionally, it is important to offer psychological sup-
port in a cost-effective way, since costs are an important
consideration for implementation of such a program
into routine care in hospitals. In attempting to control
the costs of delivering psychological interventions, the
stepped care approach has been strongly advocated as
being potentially cost-effective [28]. By using this strat-
egy, intensive and costly interventions are minimalized,
and reserved for those insufficiently helped by the initial
interventions. Stepped care attempts to maximize the ef-
ficiency of decisions about allocation of resources in
therapy, while maintaining efficacy.
We designed the TES trial, which involves Targeted se-
lection and Enhanced care, delivered on the basis of evi-
dence based Stepped care (TES). In this study, a
screening and treatment program for distress is offered
to patients with metastatic colorectal cancer (mCRC)
aiming to reduce psychological distress. Our primary
study objective is to evaluate the effectiveness of the TES
program compared to usual care in reducing psycho-
logical distress in patients with mCRC; secondary aims
include the evaluation of the impact of the TES program
on quality of life, patient evaluation of care, recognition
and management of psychological distress, and evalu-
ation of the cost-effectiveness of the TES program in
comparison with usual care.
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Study design
The study is designed as a multicenter cluster random-
ized controlled clinical trial with two treatment arms.
Sixteen hospitals, each as a separate unit, are randomly
assigned to either the TES program for screening and
treatment of psychological distress or usual care. Psycho-
logical distress, secondary outcomes and costs are evalu-
ated at baseline (T0), after 3 weeks (T3), 10 weeks
(T10), 24 weeks (T24) and 48 weeks (T48). The design
is illustrated in Figure 1.
The trial has been approved by the Medical Ethics
Committee of the VU university medical center and the
institutional ethics committees of the other participating
sites. The study is conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice
guidelines.
Patients, recruitment and setting
This multicenter study is carried out in one large Dutch
university medical center and 15 teaching hospitals. Pa-
tients are recruited from the outpatient clinics and in-
patient wards at the Departments of Medical Oncology.
Patients are eligible to participate in the study if they meet
the following inclusion criteria: diagnosis of metastatic
colorectal disease, start of treatment with 1st line chemo-
therapy, and life expectancy of more than 3 months. Ex-
clusion criteria for participation are: age < 18 or > 85 years,
insufficient command of the Dutch language, recent psy-











Figure 1 Study flow chart TES.every 2 weeks), severe psychopathology, and no informed
consent.
Randomization, treatment allocation and blinding
To allocate patients to either the TES program or to care
as usual, cluster randomization is used, with hospitals as
the unit of randomization to avoid contamination be-
tween groups. The randomization procedure is per-
formed by a statistician who is blinded for hospital
characteristics to ensure concealment of treatment allo-
cation. The random allocation of hospitals is performed
prior to patient recruitment. Accordingly, all participants
within the same hospital are randomized into the same
treatment condition (i.e. TES or usual care). Due to the
nature of the intervention, neither oncologists, nurses,
psychologists or their patients can be blinded. However,
scoring of outcome and statistical analysis is performed
blindly.
Treatment
TES program in the intervention group
The key-elements of the protocol for the TES program
are described below.
Targeted selection
Targeted selection is performed by a trained nurse/
trained clinical nurse specialist. Screening for psycho-
logical distress is implemented for patients starting with
chemotherapy, and 10 and 18 weeks later (S0, S10, and
S18 – see Figure 2). The HADS (Hospital Anxiety and*T is time of assessment 
in weeks after start with 
chemotherapy
192)














Screening S10 Screening S18 End of screening program
Diagnostic evaluation and problem 
analysis by psychologist
III Problem solving therapy
(face-to-face) by nurse
IV Psychotherapy, medication or
referral for other services
Screening
Screening
*S is time of screening
in weeks after start
chemotherapy
Screened positive for distress
Screened negative for distress
Figure 2 TES Intervention program.
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eter and corresponding Problem List) are used as
screening tools. The HADS consists of 14 questions.
There are two subscales assessing anxiety and depres-
sion, which can be combined into one scale assessing
psychological distress, with scores ranging from 0 to 42.
The cut off score for the combined anxiety and depression
scale in cancer patients is ≥ 13 [29]. The “Lastmeter”
(a combination of the Distress Thermometer ranging
from 0 to 10 with the Problem List and a single question
on the need to talk to a professional)[30] evaluates a wide
range of problems and is recommended in the Dutch
guideline “Detecting the need for psychological care” [31].
In line with this Dutch guideline, and supported byvarious studies [30,32] we apply a cut off score of 5. The
trained nurse evaluates the distress scores and offers treat-
ment to patients who score above the cut off points on ei-
ther one or both of the tools, and to patients expressing
the need to talk to a professional. Furthermore, the trained
nurse informs the oncologist when a patient has psycho-
logical distress or starts with stepped care.
Enhanced care
The entire treatment process is managed by the trained
nurse, who coordinates screening of all patients at the
appropriate moments in time (see above); evaluates the
distress scores, discusses with the patient whether he/
she wants to be involved in the treatment program
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gist about the outcome; manages and monitors the vari-
ous steps in the treatment process, as well as the
transition of the patient from one step to the next step;
and provides guidance for the patient during the entire
treatment process.
Stepped care
Treatment for psychological distress is delivered accord-
ing to the stepped care principle [33]. The steps include:
(I) watchful waiting, (II) a guided self-help program, (III)
face to face problem solving treatment (PST), and (IV)
psychotherapy, medication or a referral to other services
(e.g. social work). Patients are screened after each step,
and if psychological distress persists or if patients ex-
press the need for further guidance, a next treatment
step is offered (Figure 2).
Preferably, treatment starts at step I, and then pro-
gresses to step II, III or IV, as needed. However, if the
evaluation of the screening results indicates so, step I or
any other step can be skipped and treatment may start
at step II, III or IV. Criteria for skipping steps include
major depressive disorder, family problems, severe risk
of mood disturbance (risk factors include other major
life events, history of psychiatric problems, young age,
and little social support), the wish of the patient to skip
a step, or the opinion of the oncologist that a step needs
to be skipped.
Patients screening positive for distress at S10 or S18
are still allowed the full stepped care treatment.
Step I: Watchful waiting
The first step consists of 3 weeks “watchful waiting”, as
patients with psychological distress often recover spon-
taneously over time. This step can be chosen twice.
Step II: Guided self-help program
If distress still persists, a guided self-help program is of-
fered to the patient. A brief intervention for problem
solving in adults experiencing common psychological
symptoms such as anxiety and depression [34] has been
adjusted for patients with mCRC. Both international and
national randomized controlled studies have shown that
problem solving treatment is effective in treating psy-
chological distress [34-36]. Moreover, there is evidence
from a growing number of trials that psychological treat-
ments can be effectively delivered over the internet. A
meta-analysis revealed that the effects of internet-based
treatments for depression and anxiety disorders are
comparable to those of face to face treatments [37,38].
The intervention is available as a web based version and
as a booklet. The intervention takes approximately 5–7
weeks in total. In this period, patients describe what they
think is important in their lives, make a list of theirproblems and concerns, and divide these into three cat-
egories: important and solvable problems, unimportant
problems (problems that are not related to what is im-
portant in their lives); and important but unsolvable
problems (such as losing someone through death). For
the important and solvable problems a six-step proced-
ure of problem solving is provided. The patient analyzes
the problem and generates alternative solutions; selects
and implements the chosen solution; and evaluates the
results and prepares for the future. For the important
but unsolvable problems, the patient receives advice and
suggestions to better cope with these. Coaching is per-
formed by the researcher or research assistant and con-
sists of brief, weekly contacts by e-mail or telephone,
which take about 10 to 15 minutes per week. The coaching
is meant to give support in working through the self-help
method and is not aimed at developing a patient-therapist
relationship.
Diagnostic evaluation and problem analysis
After completing step II, all patients are screened for
psychological distress. In patients still meeting the criter-
ion for psychological distress or with the desire of psy-
chosocial support, a diagnostic evaluation and needs
assessment is made by the psychologist. The results are
used by the psychologist and patient to analyze problems
and to evaluate further need for treatment. Together, the
patient and psychologist decide on the next treatment
step: face-to-face problem solving treatment (step III) or
psychotherapy, medication or a referral (step IV), de-
pending on needs and preferences of the patient. This
problem analysis is performed in a maximum of
4 weeks.
In addition the Composite International Diagnostic
Interview (CIDI) is used for the classification of symp-
toms. This is a comprehensive, fully-structured interview
for the assessment of mental disorders according to the
definitions and criteria of ICD-10 and DSM-IV [39] and
is conducted by the research assistant by telephone.
Step III: Problem solving treatment (face-to-face)
Problem solving treatment has shown to be effective in
treating psychological distress in a wide range of somatic
conditions, including cancer [40,41]. Problem solving
treatment (face-to-face) is provided by the trained nurse,
with the individual treatment plan serving as a guide.
The treatment has a maximum of six sessions which
take place in approximately 10 weeks. The treatment
plan consists of identified problems, need for care, per-
sonalized goals, treatment and time for evaluation speci-
fied by the psychologist. The nurse is thoroughly trained
in problem solving treatment, and follows a manual in
delivering treatment [42]. If indicated, the partner is in-
volved in one of the sessions.
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services
If psychological distress persists after step (III) or if indi-
cated after diagnostic evaluation by the psychologist, the
patient is offered psychotherapy, medication prescribed
by the consultant psychiatrist, or a referral to other ser-
vices (e.g. social work). Psychotherapy is delivered accord-
ing to Dutch guidelines [43,44]. Suggested medication
includes, among others, SSRI’s and benzodiazepines.
Occasionally, antipsychotics or mood stabilizers may be
needed.Implementation of the TES program
To create a collaborative process the medical oncologist
is informed and updated about inclusion of patients in
the study and treatment provided. Besides, all psycholo-
gists and nurses are thoroughly trained in the TES
protocol, including the procedures for targeted selection,
enhanced care and stepped care. This is done in a 1-day
TES workshop. Furthermore, the approach to targeted
selection, enhanced care and the various steps in the
stepped care program are supervised by the psychologist
from VU University medical center.Usual care in control group
Detection and management of psychological distress in
hospitals assigned to the control group is not restricted
in any way. If the patient mentions psychological dis-
tress, the oncologist interviews the patient (on an ad hoc
basis, no formal screening moments for distress). During
regular visits to the department of oncology, oncologists
and nurses routinely ask for psychological distress and
provide emotional support and advise patients on how
to cope with psychological distress, on an ad hoc basis.
If urgent problems emerge, the patient is referred to a
psychological or psychiatric service.Contrast between interventions
A marked contrast between the TES program and usual
care exists. Key elements of the contrast include: formal
screening at regular intervals for psychological distress
versus ad hoc interview if a patients brings up any prob-
lems or if an oncologist or nurse recognize problems;
enhanced care in a collaborative team coordinated by a
trained nurse versus regular care delivered by oncologist
and nurse; diagnostic evaluation with a standardized
interview assessing psychological distress and problem
analysis by a psychologist versus non-standardized inter-
view by oncologist and nurse; guided self-help program,
individual face-to-face counseling, medication, or planned
referral to other services versus ad hoc support, advice
and referral to other services if needed.Assessment
Assessments are done in both treatment arms at T0, T3,
T10, T24 and T48.
Sociodemographic data
The following sociodemographic data are collected: age,
gender, social status, employment, Dutch vs non-Dutch
origin, and lifestyle characteristics.
Medical data
Collected medical data are: diagnosis, interval since diag-
nosis, initial TNM stage (classification of tumors using
the size and extension of the primary tumor (T), its
lymphatic involvement (N), and the presence of metasta-
ses (M)), cancer treatment, comorbidity, survival, re-
lapsed disease with concomitant treatment and death.
Primary outcome measures
Primary outcome is the difference in treatment effect over
time in reduction of psychological distress between the
TES program and usual care arm. Psychological distress is
measured by the Hospital Anxiety and Depression Scale
(HADS). The HADS has shown to be reliable, valid, and
responsive, and has been widely used in research on can-
cer patients (e.g. [45]). A review showed sensitivity and
specificity values for the HADS of 0.8 and higher [46].
Secondary outcome measures
Quality of life (QoL) is measured by the EORTC-QLQ-
C30 version 3.0. This is an integrated system for asses-
sing the health related quality of life of cancer pa-
tients[47]. The questionnaire incorporates five functional
scales (physical, role, cognitive, emotional, and social),
three symptom scales (fatigue, pain, and nausea and
vomiting), a global health status / QoL scale, and a num-
ber of single items assessing additional symptoms com-
monly reported by cancer patients (dyspnoea, loss of
appetite, insomnia, constipation and diarrhoea) and per-
ceived financial impact of the disease. The instrument
has been shown to be valid, reliable, and responsive to
change [33,46].
In addition to the EORTC-QLQ-C30, the RAND-36 is
used as a generic measure of health-related quality of life
[48]. The RAND-36 is a generic, short-form health sur-
vey with 36 questions and consists of 8 sub-scales: phys-
ical functioning, role physical, bodily pain, general
health, vitality, social functioning, role emotional, and
mental health. Patients’ evaluation of care is assessed
with the Client Satisfaction Questionnaire – 8 [49]. The
CSQ-8 is a validated instrument to assess patient’s satis-
faction with mental health care.
To evaluate recognition of and referral related to psy-
chological distress (e.g. to psychological or psychiatric
services) by clinicians in both treatment arms, patients’
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structured form is used to extract data from the records.Economic evaluation
The economic evaluation is conducted from both the so-
cietal and the hospital perspective. An estimation of all
relevant costs will be made in both TES and usual care:
intervention costs, healthcare costs not related to the
oncological treatment, informal care costs, and costs of
production losses due to absenteeism from paid work.
Costs of the TES intervention will be estimated using a
bottom-up approach. Costs that will be included in this
calculation are: 1) costs of the development of the inter-
vention; 2) costs of training the nurses implementing the
intervention; 3) costs of implementing the intervention.
A detailed description of resources involved in imple-
menting the TES intervention will be based on the log-
book, prospectively completed by the nurse. Healthcare
utilization outside the hospital, informal care and absen-
teeism from paid work will be assessed using an adapted
version of the TiC-P questionnaire [50]. The adapted
cost questionnaire will be administered at T10, T24, and
T48 with a recall period of 3 months.
As we assume that the oncological treatment in both
the experimental and control group of patients with
mCRC is equal, the oncological treatment costs will not
be included in the cost measurements. Absenteeism
from paid work will be valued according to the friction
cost method [47] using mean age- and gender-specific
income of the Dutch population.
Absenteeism from unpaid work and informal care is
valued using the shadow price method. The shadow
price of voluntary work and informal care is assumed to
be equal to the tariff for cleaning work.
Quality of life will be measured by the EuroQol (EQ-5D).
Quality adjusted life years (QALY’s) will be calculated by
multiplying the utility of a health state by the time spent in
this health state. The Dutch valuation tariff will be used to
value health states [48].Statistical analysis
Primary outcome is the difference in treatment effect over
time in psychological distress, as assessed with the HADS,
between the TES program and usual care. Secondary out-
comes include quality of life, patient evaluation of care,
recognition and management of psychological distress,
and costs. Data are analyzed according to the intention to
treat principle, using (mixed model) analysis of covariance.
The exact interval between assessments is modelled in the
analyses. Patients entering stepped care at S0, S10, or S18
are accounted for via a covariate in the analyses. Response
to treatment (progression or not) is accounted for via a
covariate as well.In the intention to treat analysis mixed effects models
for longitudinal data are used to deal with missing data
(attrition). Alternatively, depending on the missing data
pattern, Multiple Imputation (MI) using the Multivariate
Imputation by Chained Equations (MICE) is used to im-
pute missing effect and cost data [51-54]. The number
of imputed data sets to be created is determined based
on the fraction of missing information[55]. All datasets
are analyzed separately and the results of the separate
analyses are pooled using Rubin’s rules [56].
A complete data analysis and subgroup analysis based
on patient and treatment characteristics are performed
as secondary analyses. Additionally, during the study,
data on the pre-study number of referrals to psycho-
logical or psychiatric services is gathered at each depart-
ment of medical oncology (retrieved from medical
records). If substantial differences exist, pre-study num-
ber of referrals is used as a covariate in the analyses, to
correct for these differences.
Cost-effectiveness analyses
Both cost-effectiveness analyses (using the HADS) and
cost-utility analyses (using QALYs) will be performed.
Missing cost and effect data are imputed using multiple
imputation [54], as previously described. Differences in
costs and effects are analyzed using linear multilevel re-
gression analyses including clustering at the levels of
hospitals and/or nurses implementing TES. Adjustment
for confounding and/or effect modification is done if ne-
cessary. Incremental cost effectiveness ratios (ICERs) are
calculated by dividing the differences in mean total costs
between both treatment groups, by the difference in
mean effects between both treatment groups. To ac-
count for the typically skewed distribution of costs, bias-
corrected and accelerated bootstrapping (5000 replica-
tions) is used to estimate the 95% confidence intervals
around the mean cost differences and the uncertainty
surrounding the ICERs. To account for the clustering of
data, bootstrap replications are stratified for hospital
[57]. The bootstrapped ICERs are graphically presented
in cost-effectiveness planes. Cost-effectiveness accept-
ability curves are estimated [58,59] to show the probabil-
ity of the intervention program to be cost-effective in
comparison with usual care for a range of different ceiling
ratios, thereby showing decision uncertainty. In order to
evaluate robustness of the results, sensitivity analysis on
the most important cost drivers is performed.
Sample size calculation
The study aims to evaluate whether implementation of
screening and subsequent treatment is effective. The
power analysis takes into account that only a subset of
patients (i.e. 33%, see below) is actually treated for psy-
chological distress; the treatment effect obtained in this
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psychological distress. The power analysis addresses the
question on the effectiveness of screening and treatment
in all patients: the overall expected effect size is calcu-
lated in all patients, including patients who are actually
treated and patients who are not treated [6]. The overall
expected effect size of the implementation of screening
and subsequent treatment is calculated as follows:
i. The expected proportion of patients who are treated
for psychological distress is 33% [24,60]. In patients
who are treated for psychological distress, the
expected effect size is d’ = 0.54 [40].
ii. The expected proportion of patients who are not
treated is 67%. The expected effect size in patients
who are not treated is d” = 0.
iii. Thus, the overall expected effect size in the entire
sample is d = 0.18.
Setting the within subject correlation rho = 0.3, the
overall expected effect size d = 0.18, alpha = 0.05 (two
tail), beta = 0.80, the required sample size is 604 patients
(302 per group).
Since this is a cluster randomized trial, patients within
a cluster (i.e. hospital) cannot be assumed to be inde-
pendent. To correct for the clustering effect, the ob-
tained sample size should be inflated [61]. Assuming an
intra cluster correlation of 0.005 [62] and a cluster size
of 38 (604 divided by 16 hospitals), the obtained sample
size is multiplied by 1 + 0.005 (38–1) = 1.18 [62]. This re-
sults in 604 x 1.18 = 715 patients.
Setting the exclusion rate at 40% (primarily due to lack
of informed consent), 1192 eligible patients are required.
Patients are recruited during 28 months in 16 oncology
departments, which on average see 35 eligible patients
per year. This results in an estimate of 1300 patients.
Thus, recruitment is feasible, even taking into account a
high exclusion rate. In previously published intervention
studies on quality of life aspects, however, about 70% of
eligible patients agreed to participate [24,63,64], and an
exclusion rate of 40% seems rather pessimistic.
Discussion
With the current study, we aim to evaluate the effect-
iveness of the TES program, using screening, enhanced
care and a multi-disciplinary and stepped care oriented
approach in which well-described effective psycho-
therapeutic and pharmacotherapeutic interventions are
implemented, compared to usual care in reducing psy-
chological distress in patients with mCRC. Since symp-
toms of distress are relatively common in CRC patients
and the availability of professional support is limited,
there is a need for evidence-based knowledge regarding
effectiveness of integrated psychological care for cancerpatients who need extra support. Yet, up to now, stud-
ies on screening and treatment of psychological distress
in cancer patients have yielded mixed results. The most
important strength of the present study is that we use
targeted selection, enhanced care and effective inter-
ventions to create optimal conditions for a screening
and treatment program for psychological distress in pa-
tients with mCRC to be effective. Another strength of
the study is the clear distribution of tasks in a collab-
orative team with multiple professional disciplines
brought together. With the nurse executing a coordin-
ating role in the treatment process, the professionals
have the opportunity to deliver care efficiently. In
addition, the study follows the set of recommendations
for randomized trials made by CONSORT [65] and in
that way differentiates itself from several earlier pub-
lished studies on this issue.
An innovative aspect of this trial is that the interven-
tion aims at a balance between efforts and inputs. This
is realized by choosing for a stepped care approach, in
which patients start with the least intensive treatment
that is most likely to work, with more intensive and
costly interventions reserved for those insufficiently
helped by initial steps. To our knowledge, this is the first
trial in which the cost-effectiveness of screening and
treatment of psychological distress in CRC patients in
comparison with usual care is determined. Previous re-
search focused on cost-effectiveness of implementing a
screening programs for patients with cancer, but did not
include further psychological assessments and referral to
appropriate services [21].
A possible limitation might be that former studies re-
vealed that a large number of patients with psychological
problems do not actually use supportive psychological
resources [66]. The main reason for non-use seemed to
be patients’ belief that they do not need any help,
followed by lack of knowledge about the services pro-
vided and personal attitudes towards psychosocial treat-
ment [66]. According to another study, as many as 30%
of the patients who reported symptoms of anxiety or de-
pression declined support [67]. Since it has been found
that a significant portion of this group do not take part
in psychological support offered, a stepwise approach
will be used in the present study to individualize the
level of support needed, assuring tailored care. In such a
way we hope to increase the acceptance and accessibility
of psychological care by patients that really benefit from
treatment for psychological distress.
Another possible limitation is the homogeneity of the
study population included in the trial; results may not be
transferable to patients with cancer in general. Cancer
type specific characteristics, e.g. average age of onset,
course of disease, and associated physical impairment,
may influence patients’ level of distress and their
Schuurhuizen et al. BMC Cancer  (2015) 15:302 Page 9 of 11response to supportive psychological interventions. Re-
sults obtained from this trial in patients with mCRC
may therefore not equal those that would be found in
another cancer type. However, to evaluate the effective-
ness of the TES program we decided to restrict our
study population to this specific patient group in order
to prevent influences from different types of cancer on
the outcome.
To conclude, the present study is designed to assess
the TES program on effectiveness, with regard to psy-
chological distress, costs, quality of life, patient evalu-
ation of care, and recognition and management of
psychological distress in patients with mCRC compared
to usual care. Our results will help to resolve the con-
tinuing debate on the (cost-) effectiveness of screening
for and treatment of psychological distress in patients
with cancer. If the trial proves a successful outcome, the
TES program can be made available for implementation
on a larger scale in clinical practice.
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